| Literature DB >> 31936853 |
Congcong Wang1, Xue Gong1, Agula Bo1, Lei Zhang2, Mingxu Zhang1, Erhuan Zang1, Chunhong Zhang1,3, Minhui Li1,4.
Abstract
Iridoids are a class of active compounds that widely exist in the plant kingdom. In recent years, with advances in phytochemical research, many compounds with novel structure and outstanding activity have been identified. Iridoid compounds have been confirmed to mainly exist as the prototype and aglycone and Ι and II metabolites, by biological transformation. These metabolites have been shown to have neuroprotective, hepatoprotective, anti-inflammatory, antitumor, hypoglycemic, and hypolipidemic activities. This review summarizes the new structures and activities of iridoids identified locally and globally, and explains their pharmacokinetics from the aspects of absorption, distribution, metabolism, and excretion according to the differences in their structures, thus providing a theoretical basis for further rational development and utilization of iridoids and their metabolites.Entities:
Keywords: biological activities; iridoids; pharmacokinetics; phytochemistry
Mesh:
Substances:
Year: 2020 PMID: 31936853 PMCID: PMC7024201 DOI: 10.3390/molecules25020287
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Active iridoids compounds from 2009 to 2019.
| No. | Classes | Compounds | Sources | Ref. |
|---|---|---|---|---|
| 1 | Iridoid glycosides | Euphroside | Scrophulariaceae | [ |
| 2 | Plantarenaloside | Plantaginaceae, Bignoniaceae | [ | |
| 3 | Geniposidic acid | Scrophulariaceae, Labiatae | [ | |
| 4 | Loganic acid | Acanthaceae | [ | |
| 5 | Loganic acid-6′- | Gentianaceae | [ | |
| 6 | 2′- | Acanthaceae | [ | |
| 7 | 2′- | Rubiaceae | [ | |
| 8 | 6′- | Rubiaceae | [ | |
| 9 | Mussaenoside | Scrophulariaceae | [ | |
| 10 | Lupulinoside | Acanthaceae | [ | |
| 11 | 8-epideoxyloganic acid | Bignoniaceae | [ | |
| 12 | Shanzhiside methyl ester | Acanthaceae | [ | |
| 13 | Barlerin | Acanthaceae | [ | |
| 14 | Acetylbarlerin | Acanthaceae | [ | |
| 15 | 6- | Acanthaceae | [ | |
| 16 | 6′- | Rubiaceae | [ | |
| 17 | 6′- | Rubiaceae | [ | |
| 18 | 6′- | Rubiaceae | [ | |
| 19 | 6′- | Rubiaceae | [ | |
| 20 | Pinnatoside | Verbenaceae | [ | |
| 21 | 6β-ethoxygeniposide | Rubiaceae | [ | |
| 22 | 10- | Rubiaceae | [ | |
| 23 | Eurostoside | Scrophulariaceae | [ | |
| 24 | 10- | Rubiaceae | [ | |
| 25 | Ninpogenin | Scrophulariaceae | [ | |
| 26 | 8- | Scrophulariaceae | [ | |
| 27 | 6- | Scrophulariaceae | [ | |
| 28 | 8- | Scrophulariaceae | [ | |
| 29 | Dihydropenstemide | Plantaginaceae | [ | |
| 30 | Patrinalloside A | Valerianaceae | [ | |
| 31 | 10-isovaleroyl-dihydropenstemide | Loganiaceae | [ | |
| 32 | Buddlejoside A9 | Loganiaceae | [ | |
| 33 | 6- | Loganiaceae | [ | |
| 34 | 6- | Loganiaceae | [ | |
| 35 | 6- | Loganiaceae | [ | |
| 36 | Brasoside | Verbenaceae | [ | |
| 37 | Deacetyl asperuloside | Rubiaceae | [ | |
| 38 | Asperuloside | Rubiaceae, Plantaginaceae | [ | |
| 39 | 8α-butylgardenoside B | Rubiaceae | [ | |
| 40 | Amphicoside | Scrophulariaceae | [ | |
| 41 | Specioside | Bignoniaceae | [ | |
| 42 | Secoiridoids | 6′- | Gentianaceae | [ |
| 43 | 3′- | Gentianaceae | [ | |
| 44 | 4′- | Gentianaceae | [ | |
| 45 | Oleoside dimethyl ester | Oleaceae | [ | |
| 46 | (8 | Oleaceae | [ | |
| 47 | (8 | Oleaceae | [ | |
| 48 | (8 | Oleaceae | [ | |
| 49 | Gentiopicroside | Gentianaceae | [ | |
| 50 | Oleuropein | Oleaceae | [ | |
| 51 | Qinjiaosides B | Gentianaceae | [ | |
| 52 | Qinjiaoside A | Gentianaceae | [ | |
| 53 | 7-hydroxy eucommiol | Bignoniaceae | [ | |
| 54 | 7-methoxydiderroside | Acanthaceae | [ | |
| 55 | Isojaslanceoside B | Oleaceae | [ | |
| 56 | 6′- | Oleaceae | [ | |
| 57 | Nuezhenelenoliciside | Oleaceae | [ | |
| 58 | Bis-iridoids | Sylvestroside III | Dipsacaceae | [ |
| 59 | Cantleyosid | Dipsacaceae | [ | |
| 60 | Sylvestroside I | Dipsacaceae | [ | |
| 61 | Sylvestroside IV | Dipsacaceae | [ | |
| 62 | Laciniatoside II | Dipsacaceae | [ | |
| 63 | Sylvestroside IV | Dipsacaceae | [ | |
| 64 | sylvestroside III dimethyl | Dipsacaceae | [ | |
| 65 | Laciniatoside I | Dipsacaceae | [ | |
| 66 | Polystachyn A | Valerianaceae | [ | |
| 67 | Sclerochitonoside C | Acanthaceae | [ | |
| 68 | Oleoside dimethyl ester | Oleaceae | [ | |
| 69 | Non-glycosidic iridoids | Valtrate | Valerianaceae | [ |
| 70 | 1-β-acevaltrate | Valerianaceae | [ | |
| 71 | Acevaltrate | Valerianaceae | [ | |
| 72 | 6α-hydroxygenipi | Rubiaceae | [ | |
| 73 | 6α-methoxygenipin | Rubiaceae | [ | |
| 74 | IIHD-acevaltrate | Valerianaceae | [ | |
| 75 | garjasmine | Rubiaceae | [ |
Figure 1Three basic skeletons of iridoids.
Figure 2Chemical structures of iridoid glycosides.
Figure 3Chemical structures of secoiridoids.
Figure 4Chemical structures of bis-iridoids.
Figure 5Chemical structures of non-glycosidic iridoids.
Figure 6The pharmacological activity mechanism of iridoids. The blue arrow up indicates a positive or upregulated effect, while the red down arrow indicates a negative or downregulated effect. Orange circles represent some activity constituents, green ones represent the common pharmacological activities of iridoids, while represented enzymes and signaling pathways are illustrated by polygons. Abbreviations here represent the same meaning as in the body text.
Other activities of iridoids.
| Function | Compounds | Dose | Model | Efficacy Evaluation | Ref. |
|---|---|---|---|---|---|
| Cardiocerebrovascular activity | Geniposide | 33.2 μg/mL | Brain microvascular endothelial cell (BMEC) with oxygen–glucose deprivation (OGD) | Declining the productions of IL-8, IL-1β and monocyte chemotactic protein 1 (MCP-1) | [ |
| Digestive activity | Gentiopicroside | 20 mg/kg | Male rats (Sprague Dawley; six weeks old) | In all experimental groups an increase of gastric juice volume, total and free HCl concentration as well as pepsin concentration was observed. | [ |
| Cholagogic effects | Genipin | 1 μmol/100 g·min | Male sprague dawley rats and hyperbilirubinemic rats | Enhanced the ability of hepatocytes to secrete independent bile salts | [ |
| Antioxidant | Geniposide | 12.5, 25, 50 μg/mL | Human umbilical vein endothelial cell | Increased the activities of SOD, GSH-Px, NOS and NO production | [ |
| Antithrombotic activity | Geniposide and genipin | 20, 40 mg/kg | Male ICR mice | Significantly prolonging the time required for thrombotic occlusion | [ |
| Anti-senescence | Catalpol | 0.01, 0.1, 1 mg/mL | Human fibroblast Hs68 cell line irradiated by ultraviolet B (UVB) | Inhibited the formation of matrix metalloproteinase-1 (MMP-1) | [ |
| Against intestinal ischemia/reperfusion (I/R) injury | Catalpol | 25, 50 mg/kg | In vivo intestinal I/R-injured rats | Significantly attenuated rat intestinal I/R injury by decreasing pro-inflammatory cytokines, reducing oxidative stress, and restoring intestinal barrier function | [ |
| Anti-depressive | Genipin | 100 mg/kg | CUMS rat model | Decreases in serum trimetlylamine oxide (TMAO) and β-hydroxybutyric acid (β-HB) | [ |
| Wound healing properties | Methylcatalpol | 50 mg/kg | Male rabbits model | Protective activity against increased skin vascular permeability | [ |
| Antiallergic | 3,4-Dihydroxy catalpol | 30 mg/kg | Asthmatic mouse model | Exhibited an antiasthmatic effect by the suppression of elevated IgE, IL-4 and IL-13 levels and eosinophilia in the plasma | [ |
| Analgesic activity | Bis-iridoid | 50, 100 mg/kg | Male mice | Bis-iridoid inhibited TNF-α-induced NF-κB-dependent promoter activity in a dose-dependent manner, The release of several proinflammatory cytokines and mediators (including TNF-a andPGE2) contributes to nociceptor sensitization and a reduction | [ |
| Anti-HIV-1 activity | 2′- | 0.1 μg/mL | Real-time polymerase chain reaction (PCR) assay and HIV-1 p24 antigen kit | The expression level of C-C chemokine receptor type 5 (CCR5) and chemokine receptor type 4 (CXCR4) on CD4+ Tcellswere decreased in cells treated with this iridoid glycoside, demonstrated that this iridoid glycoside restricts HIV-1 replication on the early stage of HIV infection | [ |
| Antiproliferative activities | Deacetyl asperuloside | 806.4 μg/mL | K562 chronic myelogenous leukemic cells | Significantly increased caspase 3 activity ( | [ |
| AChE inhibitory | Lupulinoside | 134.0 μM | GST, AChE | Lupulinoside exhibited different levels of GST, AChE inhibitory | [ |
| Anti-obesity | Genipin | 20 mg/kg | High-fat diet–fed obese mice | Regulating miR-142a-5p/SREBP-1c axis, led to the inhibition of lipogenesis | [ |
| Anti-osteoporosis activity | Aucubin | 1, 2.5, 5 μM | MG63 cells | Improved osteoblast differentiation and enhanced the levels of BMP2 (bone morphogenetic proteins-2) in MG63 cells | [ |
| Nuezhenelenoliciside | - | MC3T3-E1 cells | Increased the proliferation of pre-osteoblast MC3T3-E1 cells, possessed anti-osteoporosis activity | [ | |
| Inhibition of gastric lesions | Genipin | 50, 100 mg/kg (p.o.) | HCl/ethanol-induced gastric lesions rat | Increasing ROS and ROS-induced NAPDH-oxidase (NOX) production and enabling gastric cancer cells to start the tumor cell apoptosis process via Egr1/p21 signaling pathway | [ |
| Anti- Alzheimer’s disease | Gardenoside | - | Fruit-fly Alzheimer’s disease model induced by human Abeta protein over-expression | Suppressed the expression of immune-related genes in the brain | [ |
| Anti-angiogenic | Geniposide | 25–100 μM | NIH3T3 cell line | Dose-dependently inhibiting the growth of the transformed N1H3T3 cell line | [ |
| Inhibition of rheumatoid arthritis | Geniposide | 50 μM | MH7A fibroblast-like synoviocytes in patients with rheumatoid arthritis | Inhibition of TNF-α-stimulated cell proliferation and activation of the Ras-Erk1/2 pathway via upregulating miRNA-124a expression | [ |
| α-Glucosidase inhibitory activities | Aldosecologanin | 0.5 mM | Lipopolysaccharide (LPS)-induced nitric oxide (NO) production and α-glucosidase reagent | Inhibiting α-glucosidase with IC50 values of 1.08 ± 0.70 and 0.62 ± 0.14 mM | [ |
| Anti-anxiety properties | Geniposide | 20, 40 mg/kg | Male ddY mice 4 weeks of age | Increased the social interaction time and demonstrated to exert an anxiolytic effect in a dose- dependent manner | [ |
| Antiviral | 6- | 42.2 μg/mL | The viral CPE assay | Have potent in vitro activity against respiratory syncytial virus (EC50 2.46 μg/mL, IC50 42.2 μg/mL) | [ |
| Angiogenic properties | Aucubin | 10 mg/kg | Female C57BL/6 mice | Induced angiogenesis via vascular endothelial cell growth factor (VEGF)/Akt/endothelial nitric oxide synthase (eNOS) signaling pathway | [ |
| Sedative effect | Total iridoids | 0.3, 0.6, 0.9 g/kg | Male mice | Reduce the number of autonomous activities, prolong the sleep time of mice, and strengthen the hypnotic effect of pentobarbital sodium | [ |
| Anticonvulsant | Total iridoids | 1.0, 1.5, 2.0 g/kg | Pentetrazol-induced mice epilepsy model | Reduce the mortality of mice and prolong the latent period of convulsion | [ |
| Improving irritable bowel syndrome | Total iridoids | 0.3 mg/kg | Irritable bowel syndrome model rats | Regulating TPH1 and MAO-A factor, reducing 5-HT expression in serum and visceral sensitivity in rats with irritable bowel syndrome | [ |
| Antibacterial activity | Phloyoside I, Phlomiol, Pulchelloside I | - | 12 different strains | Exhibited from low to moderate levels (MIC = 0.05–0.50 mg/mL) of antibacterial activity | [ |
| Antimalarial activity | Epoxygaertneroside, Methoxygaertneroside, Gaertneroside, Acetylgaertneroside, Gaertneric acid | 1.3, 2.3, 4.3, 5.4, and 7.1 mg/mL | MT-4 cells | Displayed antiamoebic activity with IC50 values of 1.3, 2.3, 4.3, 5.4, and 7.1 mg/mL | [ |
| DNA polymerase inhibitory | Catalpol, 8- | 47.8 mM | Adequate primer/template DNA and nucleotide analogues | Inhibition of tag DNA polymerase activity with an IC50 value of 47.8 mM | [ |
| Anti-melanogenesis activity | 9-epi-6α–methoxy geniposidic acid, Asperulosidic acid, Deacetyl asperulosidic acid, Scandoside methyl ester | 100 mM | B16 melanoma cells induced by a-melanocyte-stimulating hormone (a-MSH) | Exhibited anti-melanogenesis activity with 40–50% reduction of melanin content at 100 mM | [ |
Figure 7The metabolic processes of geniposide.
Figure 8The metabolic processes of gentiopicrin.